IL195903A0 - Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist - Google Patents

Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Info

Publication number
IL195903A0
IL195903A0 IL195903A IL19590308A IL195903A0 IL 195903 A0 IL195903 A0 IL 195903A0 IL 195903 A IL195903 A IL 195903A IL 19590308 A IL19590308 A IL 19590308A IL 195903 A0 IL195903 A0 IL 195903A0
Authority
IL
Israel
Prior art keywords
galanin
receptor antagonist
neurite outgrowth
modulating neurite
modulating
Prior art date
Application number
IL195903A
Other languages
English (en)
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of IL195903A0 publication Critical patent/IL195903A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
IL195903A 2006-06-26 2008-12-11 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist IL195903A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81668206P 2006-06-26 2006-06-26
PCT/US2007/072166 WO2008002946A2 (en) 2006-06-26 2007-06-26 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Publications (1)

Publication Number Publication Date
IL195903A0 true IL195903A0 (en) 2009-09-01

Family

ID=38738789

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195903A IL195903A0 (en) 2006-06-26 2008-12-11 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Country Status (11)

Country Link
US (1) US20080039496A1 (enExample)
EP (1) EP2032135A2 (enExample)
JP (2) JP2009541493A (enExample)
CN (1) CN101484159A (enExample)
AU (1) AU2007265088B2 (enExample)
BR (1) BRPI0712938A2 (enExample)
CA (1) CA2655829A1 (enExample)
IL (1) IL195903A0 (enExample)
MX (1) MX2008016083A (enExample)
SG (1) SG172735A1 (enExample)
WO (1) WO2008002946A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642281B2 (en) * 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
MX2011000652A (es) * 2008-07-18 2011-06-16 Dart Neuroscience Llc Metodos y sistemas para evaluar agentes para la memoria.
US20100028839A1 (en) * 2008-07-18 2010-02-04 Tully Timothy P Methods and systems for evaluating memory agents
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US8277842B1 (en) 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
BR112016026596A2 (pt) * 2014-06-26 2017-08-15 Hoffmann La Roche Derivados de indolin-2-ona ou pirrolo-piridin-2-ona, seu uso, composição farmacêutica e combinação
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
WO2017076932A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
WO2008002946A3 (en) 2008-05-02
CA2655829A1 (en) 2008-01-03
MX2008016083A (es) 2009-03-20
CN101484159A (zh) 2009-07-15
US20080039496A1 (en) 2008-02-14
JP2013227357A (ja) 2013-11-07
JP2009541493A (ja) 2009-11-26
WO2008002946A2 (en) 2008-01-03
AU2007265088A1 (en) 2008-01-03
SG172735A1 (en) 2011-07-28
BRPI0712938A2 (pt) 2013-03-26
AU2007265088B2 (en) 2013-05-23
EP2032135A2 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
IL195903A0 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
IL198825A0 (en) Substituted diazepan compounds as orexin receptor antagonists
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
ZA200903334B (en) Substituted diazepan compounds as orexin receptor antagonists
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
IL205665A0 (en) Heteroaryl derivatives as orexin receptor antagonists
ZA200807380B (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
IL192619A0 (en) Method for preparing 3-hydroxytetrahydrofuran using cyclodehydration
ZA200901124B (en) Quinuclidine derivatives as M3 antagonists
AU2008281876A8 (en) Monoamide derivatives as orexin receptor antagonists
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
IL198004A0 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
IL196094A0 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
ZA200904479B (en) Nitroderivatives as angiotensin II receptor antagonists
IL209266A0 (en) Pyrrolidine derivatives as nk2 receptor antagonists
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists